Home Search
ARDX - search results
If you're not happy with the results, please do another search
Ardelyx (ARDX), Raymond James up Price Target, Citigroup Joins the Party.
Wall Street Cozy's up to Ardelyx After New Guidance.
On January 8th, Mike Raab, President and Chief Executive...
Ardelyx (ARDX) Firmly Above Resistance.
Were not traders and we don't do technical analysis, but we could see this coming from a mile away. Next stop $9.00...
Ardelyx (ARDX) $3.40, Receives FDA Approval.
BooYah, Ardelyx shoots and we score (again) last week..but wait, there's more!
It trades down post-approval as short-term...
Is Ardelyx (ARDX) $4.00 Ready to Break Out?
We're up 160% ($579 million) in Ardelyx since adding it to the Watch List about ten months ago in November, but we...
Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Longer Term Chart
Ardelyx Enters the Danger Zone* With Tenapanor.
Booya. We’re up 143% With Ardelyx (ARDX) in Three Months – and That Ain’t...
Ardelyx Adds 16% to $3.82 as Wedbush Upgrades After Q4 Earnings.
Ardelyx ( NASDAQ: ARDX ) gained 35%...
He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Ardelyx (ARDX). Don’t be Nervous, It’s Just Money.
The Higher it Goes, The More Nervous we Get.
LIVE QUOTE
FDA to Ardelyx: “Give us a Couple More Weeks.” (ARDX) $1.80.
Oh boy, another day, another snag. There goes our Christmas bonus, dang.
LIVE QUOTE
It's been...
Latest article
COVID-19 Immunity From mRNA Booster Does Not Last Very Long.
Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to...
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
